ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Senior Automation Engineer (Sr. Engineer II) at Generate:Biomedicines - ApplyBlast

Senior Automation Engineer (Sr. Engineer II)

Generate:Biomedicines

4 days ago

4.0 on Glassdoor

Somerville, Massachusetts, United States

Onsite

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Generate Biomedicines is seeking a Senior Automation Engineer to lead and manage the automation engineering team, focusing on sustaining and advancing the wet lab platform through automated workflows for DNA and protein production, cell culture, and screening assays. The role involves designing and integrating custom instrument capabilities, driving reliability and method development, and partnering with scientists to enhance lab efficiency and scientific outcomes. This position requires strong expertise in liquid handling, workcell automation, and systems integration, along with leadership experience to guide engineers and improve scientist independence through training and documentation.

Responsibilities

Design and integrate custom instrument capabilities into wet lab platform
Manage automation engineering team and oversee day-to-day activities
Drive reliability and troubleshooting for DNA and protein production workflows

Skills

About Generate:Biomedicines

generatebiomedicines.com

Headquarters

Somerville, Massachusetts, United States

Company Size

201-500 employees

View Profile

Generate:Biomedicines is a therapeutics company that combines machine learning, computational biology, and biological engineering to design and develop precision protein medicines and antibodies. Using generative AI and lab-driven engineering, the company builds targeted biologics and epitope-focused candidates, advancing a pipeline from discovery through clinical development. Its clinical-stage programs include GB-0895, a long‑acting anti‑TSLP antibody progressing to global Phase 3 studies, and the company has recently completed an initial public offering. Generate was incubated by Flagship Pioneering and emphasizes platform-driven discovery to accelerate novel biologic therapeutics.